PL3978074T3 - Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1 - Google Patents

Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1

Info

Publication number
PL3978074T3
PL3978074T3 PL21205752.5T PL21205752T PL3978074T3 PL 3978074 T3 PL3978074 T3 PL 3978074T3 PL 21205752 T PL21205752 T PL 21205752T PL 3978074 T3 PL3978074 T3 PL 3978074T3
Authority
PL
Poland
Prior art keywords
terlipresin
hepato
treatment
syndrome type
renal syndrome
Prior art date
Application number
PL21205752.5T
Other languages
English (en)
Inventor
Khurram Jamil
Stephen Chris Pappas
Jim POTENZIANO
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Limited filed Critical Mallinckrodt Pharmaceuticals Ireland Limited
Publication of PL3978074T3 publication Critical patent/PL3978074T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
PL21205752.5T 2014-10-24 2015-10-22 Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1 PL3978074T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
PL3978074T3 true PL3978074T3 (pl) 2024-08-12

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21205752.5T PL3978074T3 (pl) 2014-10-24 2015-10-22 Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
PL15791430T PL3209317T3 (pl) 2014-10-24 2015-10-22 Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15791430T PL3209317T3 (pl) 2014-10-24 2015-10-22 Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1

Country Status (15)

Country Link
US (2) US10335452B2 (pl)
EP (3) EP3981420A1 (pl)
JP (4) JP6673915B2 (pl)
CN (2) CN107206049B (pl)
AU (1) AU2015335855A1 (pl)
CA (1) CA2965325A1 (pl)
DK (2) DK3978074T3 (pl)
ES (2) ES2904492T3 (pl)
FI (1) FI3978074T3 (pl)
HR (1) HRP20220225T1 (pl)
HU (1) HUE058066T2 (pl)
PL (2) PL3978074T3 (pl)
PT (2) PT3978074T (pl)
SI (1) SI3209317T1 (pl)
WO (1) WO2016065117A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
DK3978074T3 (da) * 2014-10-24 2024-05-13 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin til behandling af hepatorenalt syndrom type 1
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
EP3528828B1 (en) 2016-10-21 2025-01-29 Amryt Endo, Inc. Terlipressin composition for use in treating ascites
JP7579811B2 (ja) 2019-05-22 2024-11-08 バイオヴァイ インコーポレイテッド テルリプレシンの製剤
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
CN114980914A (zh) * 2019-10-30 2022-08-30 马林克罗特医疗产品知识产权公司 低平均动脉压的1型肝肾综合征患者的治疗方法
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
US20080221551A1 (en) * 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2361018B1 (en) * 2008-11-10 2015-04-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2406399B1 (en) 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
MX375116B (es) 2009-06-08 2025-03-06 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
EP2593541A4 (en) * 2010-07-14 2014-01-22 Cumberland Emerging Technologies Inc METHOD FOR THE TREATMENT OF HEPATORENAL SYNDROME AND HEPATIC ENZEPHALOPATHY WITH THROMBOXANE A2 RECEPTOR ANTAGONISTS
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
DK3978074T3 (da) * 2014-10-24 2024-05-13 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin til behandling af hepatorenalt syndrom type 1
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
HRP20220225T1 (hr) 2022-04-29
JP6673915B2 (ja) 2020-03-25
CN107206049B (zh) 2021-12-07
JP2017534618A (ja) 2017-11-24
JP2019199485A (ja) 2019-11-21
EP3209317B1 (en) 2021-12-08
US20190328831A1 (en) 2019-10-31
EP3209317A1 (en) 2017-08-30
JP2021155433A (ja) 2021-10-07
US20160113994A1 (en) 2016-04-28
PT3978074T (pt) 2024-05-13
DK3978074T3 (da) 2024-05-13
EP3978074B1 (en) 2024-03-06
US10335452B2 (en) 2019-07-02
WO2016065117A1 (en) 2016-04-28
CN114028536A (zh) 2022-02-11
FI3978074T3 (fi) 2024-05-20
SI3209317T1 (sl) 2022-05-31
EP3978074A1 (en) 2022-04-06
ES2987577T3 (es) 2024-11-15
JP6989571B2 (ja) 2022-01-05
PT3209317T (pt) 2022-01-19
HUE058066T2 (hu) 2022-06-28
CN107206049A (zh) 2017-09-26
PL3209317T3 (pl) 2022-05-23
CA2965325A1 (en) 2016-04-28
JP7346494B2 (ja) 2023-09-19
JP2022171795A (ja) 2022-11-11
CN114028536B (zh) 2024-07-09
AU2015335855A1 (en) 2017-05-18
ES2904492T3 (es) 2022-04-05
EP3981420A1 (en) 2022-04-13
DK3209317T3 (da) 2022-02-07

Similar Documents

Publication Publication Date Title
IL250016B (en) Antisense oligonucleotides for the treatment of usher syndrome type 2
IL247452A0 (en) Compounds for treatment of complement mediated disorders
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
PL3265053T3 (pl) Sposoby leczenia skóry
MA50674A (fr) Benzamides substitués 1,3-thiazol-2-yl
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
EP3564335A4 (en) SURFACE TREATMENT AGENT
DK3778595T3 (da) Pancreatitisbehandling
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
DK3231444T3 (da) Ny behandling
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3215607T3 (da) Phagterapi
BR112016022976A2 (pt) Métodos para o tratamento de hcv
IL256206A (en) Mct4 inhibitors for treating disease
KR20180084876A (ko) 내플라즈마성 부재
EP3375108A4 (en) SELECTIVE WIFI
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
DK3393478T3 (da) Kombinationsterapi
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
EP3362091A4 (en) COMBINATION THERAPY
DK3302478T3 (da) Pac-1 kombinations behandling